[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China February 25, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities of]
[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China February 25, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[Zhaopin Limited Reports Second Quarter Fiscal Year 2016 Financial Results Feb 25, 2016 PRNewswire BEIJING, Feb. 24, 2016 / Throughout the release, one ADS represents two Class A ordinary shares. Fiscal year refers to the 12 months ended June 30. Second Quarter Fiscal Year 2016 Financial Highlights Percentage growth metrics refer to second quarter fiscal year 2016 ("Q2 FY16") compared] []
[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]
[Tuniu Announces the Appointment of New Board Directors NANJING, China, Feb. 25, 2016 /PRNewswire/ -- Tuniu Corporation (Nasdaq: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced the appointment of Mr. Tie Li and Mr. Jie Zhu as directors to the Company's board of directors. The appointment of Mr. Li and Mr. Zhu is] []
[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]
